

Risk of severe COVID-19 outcomes associated with immunosuppressive and immune modifying therapies: a nationwide cohort study

DOI: [10.1101/2021.09.03.21262888](https://doi.org/10.1101/2021.09.03.21262888)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|---|---|------|-----------|
| 2 | A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data Report. Wellcome Open Research, 0, 6, 360. | 1.8 | 8 |
| 3 | Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity. Gut, 2023, 72, 410-412. | 12.1 | 5 |
| 4 | Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. Gut, 2022, 71, 1426-1439. | 12.1 | 20 |